Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropathic Pain, Epilepsy, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CACNA2D2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CACNA2D2 Recombinant Protein (HEK293 Expressed) High purity (>95%), Endotoxin <1EU/ug, Sequence Verified |
View CACNA2D2 Products |
| Gene Delivery | CACNA2D2 Lentivirus (Full-length ORF) For stable cell lines, essential for calcium channel complex assembly |
View CACNA2D2 Products |
| Benchmark Ab | Anti-CACNA2D2 Antibody (Recombinant) Positive control for western blot and binding assays |
View CACNA2D2 Products |
| Validator | CACNA2D2 siRNA Set For knockdown verification and specificity checks |
View CACNA2D2 Products |
| Related Target A | CACNA2D1 Primary gabapentinoid target; critical for selectivity counter-screening |
View CACNA2D1 Products |
| Related Target B | CACNA1A Pore-forming P/Q-type alpha-1 subunit; directly interacts with CACNA2D2 |
View CACNA1A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter screening (vs CACNA2D1/3/4) | Homolog panel proteins available, strictly sequence verified |
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity |
| Complex membrane assembly | Lentivirus delivery for stable cell line construction to preserve native conformation |
| Lack of controls | Benchmark antibodies included for assay standardization |
| False positives in screening | Valid sequence-verified siRNA for precise specificity checks |
Live CACNA2D2 R&D Tracker
Access the latest global pipeline status:
Global Clinical Landscape & Future Outlook
The race for CACNA2D2-selective therapeutics is intensifying as the field moves beyond first-generation pan-alpha2delta ligands. While gabapentin and pregabalin established clinical validation for neuropathic pain and epilepsy, their promiscuous binding across CACNA2D1 and CACNA2D2 limits therapeutic windows and contributes to CNS side effects (dizziness, somnolence, cognitive impairment). The next wave of R&D is targeting subunit-selective allosteric modulators that can dissociate analgesic efficacy from these liabilities. Concurrently, emerging evidence implicates CACNA2D2 in oncology (lung, breast) where it may act as a tumor suppressor or promoter depending on tissue context, expanding the indication landscape beyond CNS disorders to include targeted antibody-drug conjugates and checkpoint modulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Subtype-Selective) | Legacy gabapentinoid developers, CNS biotechs | Neuropathic Pain, Refractory Epilepsy, Ataxia | Selectivity assay: need human CACNA2D2 vs CACNA2D1 recombinant proteins for IC50/FACS |
| Gene Therapy (Exploratory) | Academic consortia, rare disease groups | Cerebellar Ataxia, Developmental Epileptic Encephalopathy | Expression validation: need lentivirus for stable lines, specific Abs & siRNAs |
| Monoclonal Antibody (Preclinical) | Emerging biopharma | Oncology (NSCLC, breast cancer) | Binding assays: need high-purity HEK293-expressed antigen for SPR/BLI |